Arrow International Limited

Arrow International Limited — a Maltese generic-pharmaceutical company whose principal place of business was listed as 57 St. Christopher Street, Valletta, Malta, in the 2011 complaint in the case below. It was part of the privately held Arrow Group (registered in Malta in 1999; the group dates its founding to 2000), a generics group founded by Anthony Tabatznik. Press releases reported the group at roughly 1,000 employees, ~$647M in 2008 revenue, and more than 100 molecules marketed across 20+ countries, with manufacturing in Malta (Ħal Far), Canada and Brazil. Watson Pharmaceuticals acquired the Arrow Group in December 2009 for ~$1.75B in cash, stock, preferred stock and Atorvastatin contingent payments; the entity later passed through the Watson → Actavis → Allergan Generics → Teva chain. "Arrow International Limited (Malta)" appears on Teva Pharmaceutical Industries' (NYSE: TEVA) subsidiary list as of December 31, 2023. Note the name collision with unrelated companies: Arrow International LLC (Morrisville, NC), a Teleflex medical-device subsidiary, and Arrow International, Inc. (Cleveland, OH), a charitable-gaming products maker.

Operations. Arrow develops, manufactures, markets and distributes off-patent prescription pharmaceuticals, including immediate-release solid oral dosage forms at its Maltese plant, which holds EU GMP and FDA approvals. Group commercial arms operated as Arrow Generics (UK), Cobalt Pharmaceuticals (US/Canada) and Arrow Génériques (France). In the US it also acted as a marketing and distribution partner for generics developed by third parties, which is the role that drew it into the litigation below. This is an operating generics manufacturer, not a patent-assertion entity.

Litigation posture. Defendant-only: 1 tracked case, 0 as plaintiff. That profile is consistent with an operating company defending an infringement suit rather than an NPE asserting an acquired portfolio. The sole venue is the District of New Jersey (Newark) — the plaintiff's home forum, not a plaintiff-friendly Texas venue.

Notable case. Celgene Corp. v. Natco Pharma Ltd., Arrow International Limited and Watson Laboratories, Inc., No. 2:10-cv-05197 (D.N.J., filed Oct. 8, 2010), a Hatch-Waxman action over Natco's ANDA No. 201452 for generic lenalidomide (Revlimid). Celgene ultimately asserted around 20 patents. The parties settled in December 2015; a January 4, 2016 consent judgment permitted volume-limited generic entry from March 2022 and full entry on January 1, 2026. The litigation later featured in follow-on antitrust complaints (In re Revlimid & Thalomid Purchaser Antitrust Litigation).